U.S. markets closed

Isleworth Healthcare Acquisition Corp. (ISLE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
9.990.00 (0.00%)
At close: 03:07PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close9.99
Bid9.92 x 900
Ask9.99 x 1100
Day's Range9.98 - 9.99
52 Week Range9.66 - 9.99
Avg. Volume51,285
Market Cap261.65M
Beta (5Y Monthly)N/A
PE Ratio (TTM)63.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-24% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ISLE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Isleworth Healthcare Acquisitio
    Analyst Report: Boyd Gaming Corp.Boyd Gaming, based in Las Vegas, owns and operates 29 gaming properties, up from 16 in 2011. The company's properties are located in Nevada, Iowa, Mississippi, Indiana, Illinois, Kansas, Missouri, Ohio, Pennsylvania and Louisiana. With a market cap of $6.0 billion, BYD is generally considered a mid-cap growth stock.
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • PR Newswire


    Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agr

  • PR Newswire

    Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress

    Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.

  • PR Newswire

    Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress

    Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online.